learn GT20029
research compound made to degrade androgen receptors in scalp
Search
forLearn
2 / 2 resultslearn Pyrilutamide
highly targeted anti-androgen that might have minimal systemic effects
Research
5 / 1000+ results
research Efficient Silencing of Androgen Receptor Gene via UTR-Targeting siRNAs for Androgenetic Alopecia Therapy
AR-27 E-Chol siRNA can effectively regrow hair by reducing androgen receptor gene activity.
research Efficient Silencing of Androgen Receptor Gene via UTR-Targeting siRNAs for Androgenetic Alopecia Therapy
AR-27 E-Chol siRNA can effectively promote hair regrowth for androgenetic alopecia.
research Trends in the Development of New Drugs for the Treatment of Benign Prostatic Hyperplasia
New treatments for enlarged prostate are being developed to be more effective and have fewer side effects.
research Cell Surface Receptor Kinase FERONIA Linked to Nutrient Sensor TORC Signaling Controls Root Hair Growth at Low Temperature Linked to Low Nitrate in Arabidopsis Thaliana
A protein called FERONIA helps control root hair growth in response to cold and low nitrogen by activating nutrient-sensing pathways in a plant called Arabidopsis.
research Isotretinoin Treatment Upregulates the Expression of P53 in the Skin and Sebaceous Glands of Patients with Acne Vulgaris
Acne treatment with isotretinoin increases the presence of p53, a protein, in skin and oil glands, which may help reduce acne severity.
Community Join
5 / 684 resultscommunity How long until pyrilutamide or gt20029 get FDA approved?
Hair loss treatments pyrilutamide and GT20029 discussed. Pyrilutamide approval in 2 years, GT20029 in 5-6+ years.
community Kintor Pharma Announces Completion of Subject Enrollment and Dosing in Phase I Clinical Trial of AR-PROTAC(GT20029) in the US_Kintor Pharmaceutical Limited
Kintor Pharma finished enrolling and dosing participants in a Phase I trial for a hair loss treatment called AR-PROTAC (GT20029). The effectiveness of another drug, pyrilutamide (KX-826), for hair loss will be clearer after a Phase 2 trial expected to complete in January 2023.
community Kintor's email response to me, regarding false advertising, and my proposal for them to develop a topical dut formulation with meaningful efficacy.
Kintor apologized for using misleading images in their advertisements and promised stricter review processes. They are also considering developing a topical dutasteride formulation.
community PYRILUTAMIDE PHASE 3 RESULTS : No statistical significance
The phase 3 trial results for Pyrilutamide showed no significant difference from the control treatment in increasing hair count, leading to the company halting its development. Users discussed their disappointment and skepticism about hair loss treatments, with some mentioning other treatments like Minoxidil, Finasteride, and RU58841.
community Information regarding Kintor’s GT20029
The conversation discusses skepticism about the effectiveness of new hair loss treatments, mentioning that despite 40 years of research, only accidental discoveries like Minoxidil and Finasteride have been made. It also notes that drug development is a slow process, often taking a decade or more to bring a new drug to market.